Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3) (ATTRACT)

Poitiers University Hospital

Status and phase

Completed

Phase 4

Conditions

Type 3 Choroidal Neovascularization

Treatments

Drug: Aflibercept

Study type

Interventional

Funder types

Other

Identifiers

NCT02320474

ATTRACT (Other Identifier)

Details and patient eligibility

About

This is a one-year pilot, interventional, prospective, single arm, non-randomized, multicentric (3 centers) controlled study that aims to evaluate the response of type 3 choroidal neovascularization to treatment by Aflibercept following a classic protocol.

Enrollment

26 patients

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Males or females aged more than 50 years
Patients with type 3 choroidal neovascularization assessed on FA, ICG and OCT
Exudation on SD-OCT scans defined by intraretinal cysts or subretinal fluid.
Best Corrected Visual Acuity at inclusion between 24 and 78 letters (ETDRS)
Media clarity, pupillary dilation and patient cooperation sufficient to allow fundus photographs of adequate quality

Exclusion criteria

Any contraindications as reported in the labelling of Aflibercept (Eylea®): Ocular or periocular infection, Active intraocular inflammation or Hypersensitivity.
Any previous history of intravitreal injections in the study eye for exudative AMD
Any secondary chorioretinal anastomosis due to retinal scar or fibrosis
Any history of vitrectomy
Media opacities preventing accurate imaging of the retina (cataract)
Any other retinal disorder possibly associated with type 3 CNV (epiretinal membrane, macular hole)
Confirmed intraocular pressure ≥25 mmHg or non-stable glaucoma.